Novartis AG (NVS) DCF Valuation

Novartis AG (NVS) DCF Valuation

CH | Healthcare | Drug Manufacturers - General | NYSE
Novartis AG (NVS) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Novartis AG (NVS) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Novartis AG? Our (NVS) DCF Calculator integrates real-world data with comprehensive customization features, allowing you to adjust forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 48,677.0 49,898.0 52,877.0 51,828.0 46,660.0 46,254.4 45,852.4 45,453.9 45,058.8 44,667.1
Revenue Growth, % 0 2.51 5.97 -1.98 -9.97 -0.86919 -0.86919 -0.86919 -0.86919 -0.86919
EBITDA 15,009.0 15,236.0 17,132.0 14,726.0 18,286.0 14,928.2 14,798.5 14,669.9 14,542.4 14,416.0
EBITDA, % 30.83 30.53 32.4 28.41 39.19 32.27 32.27 32.27 32.27 32.27
Depreciation 5,826.0 5,110.0 5,429.0 6,705.0 8,277.0 5,842.2 5,791.4 5,741.1 5,691.2 5,641.7
Depreciation, % 11.97 10.24 10.27 12.94 17.74 12.63 12.63 12.63 12.63 12.63
EBIT 9,183.0 10,126.0 11,703.0 8,021.0 10,009.0 9,086.1 9,007.1 8,928.8 8,851.2 8,774.2
EBIT, % 18.87 20.29 22.13 15.48 21.45 19.64 19.64 19.64 19.64 19.64
Total Cash 11,446.0 11,563.0 28,329.0 18,930.0 13,962.0 15,422.2 15,288.1 15,155.2 15,023.5 14,892.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 9,172.0 9,073.0 8,828.0 8,936.0 8,124.0
Account Receivables, % 18.84 18.18 16.7 17.24 17.41
Inventories 5,982.0 7,131.0 6,666.0 7,175.0 5,913.0 6,078.1 6,025.3 5,972.9 5,921.0 5,869.6
Inventories, % 12.29 14.29 12.61 13.84 12.67 13.14 13.14 13.14 13.14 13.14
Accounts Payable 5,424.0 5,403.0 5,553.0 5,146.0 4,926.0 4,899.2 4,856.6 4,814.4 4,772.5 4,731.0
Accounts Payable, % 11.14 10.83 10.5 9.93 10.56 10.59 10.59 10.59 10.59 10.59
Capital Expenditure -2,257.0 -2,585.0 -2,971.0 -2,671.0 -2,753.0 -2,450.5 -2,429.2 -2,408.1 -2,387.2 -2,366.4
Capital Expenditure, % -4.64 -5.18 -5.62 -5.15 -5.9 -5.3 -5.3 -5.3 -5.3 -5.3
Tax Rate, % -62.78 -62.78 -62.78 -62.78 -62.78 -62.78 -62.78 -62.78 -62.78 -62.78
EBITAT 7,341.3 8,274.7 10,755.5 6,664.2 16,292.2 7,934.8 7,865.9 7,797.5 7,729.7 7,662.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1,180.3 9,728.7 14,073.5 9,674.2 23,670.2 11,083.2 11,309.4 11,211.1 11,113.6 11,017.0
WACC, % 6.46 6.47 6.52 6.48 6.56 6.5 6.5 6.5 6.5 6.5
PV UFCF
SUM PV UFCF 46,339.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 11,237
Terminal Value 249,768
Present Terminal Value 182,308
Enterprise Value 228,648
Net Debt 12,955
Equity Value 215,693
Diluted Shares Outstanding, MM 2,092
Equity Value Per Share 103.10

What You Will Receive

  • Pre-Filled Financial Model: Novartis AG's (NVS) actual data facilitates accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other critical factors.
  • Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Flexible and Reusable: Designed for adaptability, allowing for repeated use in detailed forecasting.

Key Features

  • Pre-Loaded Data: Novartis AG’s historical financial statements and pre-filled forecasts.
  • Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Instant Results: View Novartis AG’s intrinsic value recalculating in real time.
  • Clear Visual Outputs: Dashboard charts present valuation results and key metrics effectively.
  • Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.

How It Works

  • Download: Get the pre-built Excel file containing Novartis AG's (NVS) financial data.
  • Customize: Modify forecasts, including sales growth, EBITDA margin, and discount rate.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various projections and instantly analyze different outcomes.
  • Make Decisions: Leverage the valuation insights to inform your investment choices.

Why Choose This Calculator for Novartis AG (NVS)?

  • Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and healthcare consultants.
  • Comprehensive Data: Novartis’ historical and projected financials preloaded for precise analysis.
  • Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Clear Results: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance helps you navigate the calculations with ease.

Who Should Use This Product?

  • Investors: Evaluate Novartis AG’s valuation prior to making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation workflows and assess financial forecasts.
  • Startup Founders: Understand the valuation methods applied to large pharmaceutical companies like Novartis AG.
  • Consultants: Provide detailed valuation analyses and reports for clients in the healthcare sector.
  • Students and Educators: Utilize current data to learn and instruct on valuation methodologies.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring in-depth valuation calculations.
  • Real-World Data: Novartis AG's (NVS) historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore different scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.

No products were found matching.